Revolutionizing drug development: harnessing the potential of organ-on-chip technology for disease modeling and drug discovery

47Citations
Citations of this article
134Readers
Mendeley users who have this article in their library.

Abstract

The inefficiency of existing animal models to precisely predict human pharmacological effects is the root reason for drug development failure. Microphysiological system/organ-on-a-chip technology (organ-on-a-chip platform) is a microfluidic device cultured with human living cells under specific organ shear stress which can faithfully replicate human organ-body level pathophysiology. This emerging organ-on-chip platform can be a remarkable alternative for animal models with a broad range of purposes in drug testing and precision medicine. Here, we review the parameters employed in using organ on chip platform as a plot mimic diseases, genetic disorders, drug toxicity effects in different organs, biomarker identification, and drug discoveries. Additionally, we address the current challenges of the organ-on-chip platform that should be overcome to be accepted by drug regulatory agencies and pharmaceutical industries. Moreover, we highlight the future direction of the organ-on-chip platform parameters for enhancing and accelerating drug discoveries and personalized medicine.

Cite

CITATION STYLE

APA

Sunildutt, N., Parihar, P., Chethikkattuveli Salih, A. R., Lee, S. H., & Choi, K. H. (2023). Revolutionizing drug development: harnessing the potential of organ-on-chip technology for disease modeling and drug discovery. Frontiers in Pharmacology. Frontiers Media SA. https://doi.org/10.3389/fphar.2023.1139229

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free